NEW YORK, NY / ACCESSWIRE / October 12, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Katapult Holdings, Inc. (NASDAQ:KPLT)
CONTACT JAKUBOWITZ ABOUT KPLT:
https://claimyourloss.com/securities/katapult-holdings-inc-loss-submission-form/?id=20349&from=1
Class Period: December 18, 2020 - August 10, 2021
Lead Plaintiff Deadline: October 26, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Katapult was experiencing declining e-commerce retail sales and consumer spending, (2) despite Katapult's assertions that it was clear and compelling value proposition to both consumers and merchants, transforming the way nonprime consumers shop for essential goods and enabling merchant access to this underserved segment, Katapult lacked visibility into its consumers' future buying behavior; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.
Cassava Sciences, Inc. (NASDAQ:SAVA)
CONTACT JAKUBOWITZ ABOUT SAVA:
https://claimyourloss.com/securities/cassava-sciences-inc-loss-submission-form/?id=20349&from=1
Class Period: September 14, 2020 - August 27, 2021
Lead Plaintiff Deadline: October 26, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.
The Honest Company, Inc. (NASDAQ:HNST)
CONTACT JAKUBOWITZ ABOUT HNST:
https://claimyourloss.com/securities/the-honest-company-inc-loss-submission-form/?id=20349&from=1
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Honest common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's May 2021 initial public offering.
Lead Plaintiff Deadline: November 15, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) prior to the Initial Public Offering ("IPO"), the Company's results had been significantly impacted by a multimillion-dollar COVID-19 stock-up for products in the Diapers and Wipes category and Household and Wellness category; (2) at the time of the IPO, the Company was experiencing decelerating demand for such products; (3) as a result, the Company's financial results would likely be adversely impacted; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law